C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 76 filers reported holding C4 THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $169,245 | -32.5% | 90,992 | -0.2% | 0.00% | – |
| Q2 2023 | $250,685 | -79.2% | 91,158 | -76.3% | 0.00% | – |
| Q1 2023 | $1,207,656 | -48.7% | 384,604 | -3.6% | 0.00% | – |
| Q4 2022 | $2,354,288 | -29.7% | 399,032 | +4.5% | 0.00% | -100.0% |
| Q3 2022 | $3,350,000 | +19.9% | 381,983 | +3.1% | 0.00% | 0.0% |
| Q2 2022 | $2,793,000 | -67.0% | 370,520 | +6.1% | 0.00% | 0.0% |
| Q1 2022 | $8,474,000 | -27.2% | 349,262 | -3.4% | 0.00% | -50.0% |
| Q4 2021 | $11,648,000 | -28.4% | 361,696 | -0.6% | 0.00% | -33.3% |
| Q3 2021 | $16,261,000 | +41.7% | 363,953 | +20.0% | 0.00% | +50.0% |
| Q2 2021 | $11,479,000 | +160.6% | 303,379 | +154.8% | 0.00% | +100.0% |
| Q1 2021 | $4,405,000 | +6.3% | 119,076 | -4.8% | 0.00% | 0.0% |
| Q4 2020 | $4,144,000 | – | 125,070 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $15,939,000 | 8.67% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $54,406,000 | 3.42% |
| Darwin Global Management, Ltd. | 228,595 | $7,573,000 | 2.11% |
| Asymmetry Capital Management, L.P. | 139,343 | $4,616,000 | 2.10% |
| Cormorant Asset Management, LP | 2,490,065 | $80,021,000 | 1.90% |
| Logos Global Management LP | 477,928 | $15,834,000 | 1.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 443,824 | $14,601,000 | 1.30% |
| Soleus Capital Management, L.P. | 268,548 | $8,897,000 | 1.17% |
| P.A.W. CAPITAL CORP | 40,000 | $1,325,000 | 1.17% |
| RTW INVESTMENTS, LP | 2,149,228 | $68,679,000 | 1.15% |